Clinical effect of flavored Astragalus Jianzhong decoction in treating diarrheal irritable bowel syndrome
加味黄芪建中汤治疗腹泻型肠易激综合征的临床疗效

摘要

目的 分析加味黄芪建中汤用于腹泻型肠易激综合征的价值。方法 对2020年8月-2022年7月本科接诊腹泻型肠易激综合征病人（n=84）进行随机分组，试验和对照组各42人，前者用加味黄芪建中汤，后者行常规治疗。对比复发率等指标。结果 关于总有效率，试验组数据97.62%，和对照组数据80.95%相比更高（P＜0.05）。关于中医证候积分，治疗结束时：试验组数据（4.02±1.07）分，和对照组数据（7.36±1.38）分相比更低（P＜0.05）。关于复发率：试验组数据4.76%，和对照组数据23.81%相比更低（P＜0.05）。关于sf-36评分：治疗结束时，试验组数据（89.51±2.63）分，和对照组数据（80.42±3.15）分相比更高（P＜0.05）。结论 腹泻型肠易激综合征用加味黄芪建中汤，复发率更低，疗效更高，症状缓解更为迅速，生活质量改善更加明显。

Abstract

Objective: To analyze the value of flavored Astragalus Jianzhong decoction for diarrhea type irritable bowel syndrome.
Methods: For the diarrhea patients (n=84) from August 2020 to July 2022,42 patients were each in the control group, the former used flavored Astragalus Jianzhong soup, and the latter underwent routine treatment. Compare the recurrence rate and other indicators.
Results: Regarding the total response rate, the test group data was 97.62%, much higher than 80.95% in the control group (P <0.05). For the TCM syndrome score, at the end of the treatment: the test group data (4.02 ± 1.07) score was lower than the control group data (7.36 ± 1.38) score (P <0.05). On the recurrence rate: the trial group data was 4.76%, which was even lower than the 23.81% data in the control group (P <0.05). For sf-36 score: At the end of treatment, the trial group data (89.51 ± 2.63) score was higher than the control group data (80.42 ± 3.15) score (P <0.05).
Conclusion  : For diarrhea-type irritable bowel syndrome, there is a lower recurrence rate, a higher efficacy, a more rapid symptom relief, and a better improvement in the quality of life.